Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2014. The report documents the results of an extraordinary general meeting of shareholders held on January 6, 2014.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing.
Corporate Actions and Governance
Shareholders and American Depositary Receipt holders adopted resolutions to:
- Comply with the reporting requirements of the U.S. Securities Exchange Act of 1934 in lieu of compliance with Section F of the Israeli Securities Law.
- Approve the Company's compensation policies pursuant to Section 267A of the Israeli Companies Law.
An English translation of the meeting results is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Confirmation of the shareholder vote results regarding the shift in regulatory reporting compliance from Israeli to U.S. standards.
- Details of the approved compensation policies under Israeli law.
- Review of Exhibit 99.1 for the full text of the meeting resolutions.